Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma
Abstract
:1. Introduction
2. Results
2.1. The Distribution of PD-1 and PD-L1 Expression in Human Organs
2.2. Peripheral Blood Expression of PD-1 and Immune Profiles in Melanoma
2.3. Tumor Site Expression of PD-1/PD-L1 and Immune Profiles
2.4. A High Frequency of Lin−CD11c+HLA-DR+-Activated DCs in Responders to Nivolumab
3. Discussion
4. Materials and Methods
4.1. Patients
4.2. Flow Cytometric Analysis
4.3. Microarray Data Analysis
4.4. Statistical Analysis
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Jenkins, R.W.; Fisher, D.E. Treatment of advanced melanoma in 2020 and beyond. J. Investig. Dermatol. 2021, 141, 23–31. [Google Scholar] [CrossRef] [PubMed]
- Zeng, H.; Judson-Torres, R.L.; Shain, A.H. The evolution of melanoma—Moving beyond binary models of genetic progression. J. Investig. Dermatol. 2020, 140, 291–297. [Google Scholar] [CrossRef] [PubMed]
- Robert, C.; Long, G.V.; Brady, B.; Dutriaux, C.; Maio, M.; Mortier, L.; Hassel, J.C.; Rutkowski, P.; McNeil, C.; Kalinka-Warzocha, E.; et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015, 372, 320–330. [Google Scholar] [CrossRef] [Green Version]
- Friedman, C.F.; Proverbs-Singh, T.A.; Postow, M.A. Treatment of the immune-related adverse effects of immune checkpoint inhibitors. JAMA Oncol. 2016, 2, 1346–1353. [Google Scholar] [CrossRef]
- Freeman-Keller, M.; Kim, Y.; Cronin, H.; Richards, A.; Gibney, G.T.; Weber, J.S. Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes. Clin. Cancer Res. 2016, 22, 886–894. [Google Scholar] [CrossRef] [Green Version]
- Nishimura, H.; Nose, M.; Hiai, H.; Minato, N.; Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunology 1999, 11, 141–151. [Google Scholar] [CrossRef] [Green Version]
- Nishimura, H.; Okazaki, T.; Tanaka, Y.; Nakatani, K.; Hara, M.; Matsumori, A.; Sasayama, S.; Mizoguchi, A.; Hiai, H.; Minato, N.; et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001, 291, 319–322. [Google Scholar] [CrossRef]
- Okazaki, T.; Honjo, T. The PD-1–PD-L pathway in immunological tolerance. Trends Immunol. 2006, 27, 195–201. [Google Scholar] [CrossRef]
- Appay, V.; Jandus, C.; Voelter, V.; Reynard, S.; Coupland, S.E.; Rimoldi, D.; Lienard, D.; Guillaume, P.; Krieg, A.M.; Cerottini, J.-C.; et al. New generation vaccine induces effective melanoma-specific CD8+T cells in the circulation but not in the tumor site. J. Immunol. 2006, 177, 1670–1678. [Google Scholar] [CrossRef] [Green Version]
- Arienti, F.; Sulé-Suso, J.; Belli, F.; Mascheroni, L.; Rivoltini, L.; Melani, C.; Maio, M.; Cascinelli, N.; Colombo, M.P.; Parmiani, G. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum. Gene Ther. 1996, 7, 1955–1963. [Google Scholar] [CrossRef]
- Lee, K.H.; Panelli, M.C.; Kim, C.J.; Riker, A.I.; Bettinotti, M.P.; Roden, M.M.; Fetsch, P.; Abati, A.; Rosenberg, S.A.; Marincola, F.M. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J. Immunol. 1998, 161, 4183–4194. [Google Scholar] [PubMed]
- Baurain, J.-F.; Colau, D.; Van Baren, N.; Landry, C.; Martelange, V.; Vikkula, M.; Boon, T.; Coulie, P.G. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene. J. Immunol. 2000, 164, 6057–6066. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Polak, M.E.; Borthwick, N.J.; Gabriel, F.G.; Johnson, P.; Higgins, B.; Hurren, J.; McCormick, D.; Jager, M.J.; Cree, I.A. Mechanisms of local immunosuppression in cutaneous melanoma. Br. J. Cancer 2007, 96, 1879–1887. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wolchok, J.D.; Neyns, B.; Linette, G.; Negrier, S.; Lutzky, J.; Thomas, L.; Waterfield, W.; Schadendorf, D.; Smylie, M.; Guthrie, T.; et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010, 11, 155–164. [Google Scholar] [CrossRef]
- Amar, A.P.; Weiss, M.H. Pituitary anatomy and physiology. Neurosurg. Clin. N. Am. 2003, 14, 11–23. [Google Scholar] [CrossRef]
- Leblond, C.P.; Gross, J. The mechanism of the secretion of thyroid hormone. J. Clin. Endocrinol. Metab. 1949, 9, 149–157. [Google Scholar] [CrossRef]
- Ekins, R. Measurement of free hormones in blood. Endocr. Rev. 1990, 11, 5–46. [Google Scholar] [CrossRef] [PubMed]
- Weber, J.S.; Postow, M.; Lao, C.D.; Schadendorf, D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist 2016, 21, 1230–1240. [Google Scholar] [CrossRef] [Green Version]
- Ferrari, S.M.; Fallahi, P.; Elia, G.; Ragusa, F.; Ruffilli, I.; Patrizio, A.; Galdiero, M.R.; Baldini, E.; Ulisse, S.; Marone, G.; et al. Autoimmune endocrine dysfunctions associated with cancer immunotherapies. Int. J. Mol. Sci. 2019, 20, 2560. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xu, W.; Moor, R.J.; Walpole, E.T.; Atkinson, V.G. Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: Case report and review of the literature. Melanoma Res. 2019, 29, 333–337. [Google Scholar] [CrossRef] [PubMed]
- Bucheit, A.D.; Hardy, J.T.; Szender, J.B.; Oliva, I.C.G. Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition. Melanoma Res. 2020, 30, 423–425. [Google Scholar] [CrossRef] [PubMed]
- Nakamura, M.; Mashima, E.; Yamaguchi, T.; Sasaki, N.; Hara, Y.; Omoto, D.; Haruyama, S.; Yoshioka, M.; Nishio, D.; Sakuragi, Y.; et al. Nivolumab in the treatment of malignant melanoma: Review of the literature. OncoTargets Ther. 2015, 8, 2045–2051. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- D’Addio, F.; Riella, L.V.; Mfarrej, B.G.; Chabtini, L.; Adams, L.T.; Yeung, M.; Yagita, H.; Azuma, M.; Sayegh, M.H.; Guleria, I. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J. Immunol. 2011, 187, 4530–4541. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Poulet, F.M.; Wolf, J.J.; Herzyk, D.J.; DeGeorge, J.J. An evaluation of the impact of PD-1 pathway blockade on reproductive safety of therapeutic PD-1 inhibitors. Birth Defects Res. Part B Dev. Reprod. Toxicol. 2016, 107, 108–119. [Google Scholar] [CrossRef]
- Merchant, M.S.; Wright, M.; Baird, K.; Wexler, L.H.; Rodriguez-Galindo, C.; Bernstein, D.; Delbrook, C.; Lodish, M.B.; Bishop, R.J.; Wolchok, J.D.; et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin. Cancer Res. 2015, 22, 1364–1370. [Google Scholar] [CrossRef] [Green Version]
- Latchman, Y.E.; Liang, S.C.; Wu, Y.; Chernova, T.; Sobel, R.A.; Klemm, M.; Kuchroo, V.K.; Freeman, G.J.; Sharpe, A.H. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl. Acad. Sci. USA 2004, 101, 10691–10696. [Google Scholar] [CrossRef] [Green Version]
- Krieg, C.; Nowicka, M.; Guglietta, S.; Schindler, S.; Hartmann, F.J.; Weber, L.M.; Dummer, R.; Robinson, M.D.; Levesque, M.P.; Becher, B. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat. Med. 2018, 24, 144–153. [Google Scholar] [CrossRef]
- Damsky, W.; Jilaveanu, L.; Turner, N.; Perry, C.; Zito, C.; Tomayko, M.; Leventhal, J.; Herold, K.; Meffre, E.; Bosenberg, M.; et al. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. J. Immunother. Cancer 2019, 7, 153. [Google Scholar] [CrossRef] [Green Version]
- Perricone, M.A.; Smith, K.A.; Claussen, K.A.; Plog, M.S.; Hempel, D.M.; Roberts, B.L.; George, J.A.S.; Kaplan, J.M. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J. Immunother. 2004, 27, 273–281. [Google Scholar] [CrossRef]
- Zhang, Y.; Gallastegui, N.; Rosenblatt, J.D. Regulatory B cells in anti-tumor immunity. Int. Immunol. 2015, 27, 521–530. [Google Scholar] [CrossRef]
- Selitsky, S.R.; Mose, L.E.; Smith, C.C.; Chai, S.; Hoadley, K.A.; Dittmer, D.P.; Moschos, S.J.; Parker, J.S.; Vincent, B.G. Prognostic value of B cells in cutaneous melanoma. Genome Med. 2019, 11, 1–11. [Google Scholar] [CrossRef] [Green Version]
- Tam, Y.K.; Miyagawa, B.; Ho, V.C.; Klingemann, H.-G. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK. J. Hematother. 1999, 8, 281–290. [Google Scholar] [CrossRef] [PubMed]
- Yajima, T.; Nishimura, H.; Wajjwalku, W.; Harada, M.; Kuwano, H.; Yoshikai, Y. Overexpression of interleukin-15in vivo enhances antitumor activity against mhc class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response. Int. J. Cancer 2002, 99, 573–578. [Google Scholar] [CrossRef] [PubMed]
- Sugiura, D.; Maruhashi, T.; Okazaki, I.-M.; Shimizu, K.; Maeda, T.K.; Takemoto, T.; Okazaki, T. Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses. Science 2019, 364, 558–566. [Google Scholar] [CrossRef] [PubMed]
- Vilain, R.E.; Menzies, A.M.; Wilmott, J.S.; Kakavand, H.; Madore, J.; Guminski, A.; Liniker, E.; Kong, B.Y.; Cooper, A.J.; Howle, J.R.; et al. Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. Clin. Cancer Res. 2017, 23, 5024–5033. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yoshikawa, S.; Kiyohara, Y.; Otsuka, M.; Kondou, R.; Nonomura, C.; Miyata, H.; Iizuka, A.; Ohshima, K.; Urakami, K.; Nagashima, T.; et al. Multi-omics profiling of patients with melanoma treated with nivolumab in project HOPE. Anticancer Res. 2017, 37, 1321–1328. [Google Scholar] [CrossRef] [Green Version]
- Weber, J.S.; Kudchadkar, R.R.; Yu, B.; Gallenstein, D.; Horak, C.E.; Inzunza, H.D.; Zhao, X.; Martinez, A.J.; Wang, W.; Gibney, G.; et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipili-mumab-refractory or -naive melanoma. J. Clin. Oncol. 2013, 31, 4311–4318. [Google Scholar] [CrossRef] [Green Version]
- Johnson, D.B.; Estrada, M.V.; Salgado, R.; Sanchez, V.; Doxie, D.B.; Opalenik, S.R.; Vilgelm, A.E.; Feld, E.; Johnson, A.S.; Greenplate, A.R.; et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat. Commun. 2016, 7, 10582. [Google Scholar] [CrossRef] [Green Version]
- Kasanen, H.; Hernberg, M.; Mäkelä, S.; Brück, O.; Juteau, S.; Kohtamäki, L.; Ilander, M.; Mustjoki, S.; Kreutzman, A. Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients. Cancer Immunol. Immunother. 2020, 69, 717–730. [Google Scholar] [CrossRef] [Green Version]
- Nonomura, Y.; Otsuka, A.; Nakashima, C.; Seidel, J.A.; Kitoh, A.; Dainichi, T.; Nakajima, S.; Sawada, Y.; Matsushita, S.; Aoki, M.; et al. Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients. OncoImmunology 2016, 5, e1248327. [Google Scholar] [CrossRef]
- Takeuchi, Y.; Tanemura, A.; Tada, Y.; Katayama, I.; Kumanogoh, A.; Nishikawa, H. Clinical response to PD-1 blockade cor-relates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. Int. Immunol. 2018, 30, 13–22. [Google Scholar] [CrossRef]
- Gide, T.N.; Quek, C.; Menzies, A.M.; Tasker, A.T.; Shang, P.; Holst, J.; Madore, J.; Lim, S.Y.; Velickovic, R.; Wongchenko, M.; et al. Distinct immune cell populations define response to An-ti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy. Cancer Cell 2019, 35, 238–255.e6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, C.; He, H.; Li, X.; Su, M.A.; Cao, Y. Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy. Br. J. Cancer 2019, 120, 346–355. [Google Scholar] [CrossRef] [Green Version]
- Grasso, C.S.; Tsoi, J.; Onyshchenko, M.; Abril-Rodriguez, G.; Ross-Macdonald, P.; Wind-Rotolo, M.; Champhekar, A.; Medina, E.; Torrejon, D.Y.; Shin, D.S.; et al. Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma. Cancer Cell 2020, 38, 500–515.e3. [Google Scholar] [CrossRef] [PubMed]
- Saito, R.; Sawada, Y.; Saito-Sasaki, N.; Yamamoto, K.; Yoshioka, H.; Ohmori, S.; Yoshioka, M.; Okada, E.; Nakamura, M. Profile fluctuation of peripheral blood in advanced melanoma patients treated with nivolumab. J. Dermatol. 2018, 45, 1452–1455. [Google Scholar] [CrossRef]
- Sawada, Y.; Nakamura, M.; Kabashima-Kubo, R.; Shimauchi, T.; Kobayashi, M.; Tokura, Y. Defective epidermal innate immunity and resultant superficial dermatophytosis in adult T-cell leukemia/lymphoma. Clin. Cancer Res. 2012, 18, 3772–3779. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- She, X.; Rohl, C.A.; Castle, J.C.; Kulkarni, A.V.; Johnson, J.M.; Chen, R. Definition, conservation and epigenetics of housekeeping and tissue-enriched genes. BMC Genom. 2009, 10, 269. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Smith, A.P.; Hoek, K.; Becker, D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol. Ther. 2005, 4, 1018–1029. [Google Scholar] [CrossRef] [Green Version]
- Xu, L.; Shen, S.S.; Hoshida, Y.; Subramanian, A.; Ross, K.; Brunet, J.-P.; Wagner, S.N.; Ramaswamy, S.; Mesirov, J.P.; Hynes, R.O. Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol. Cancer Res. 2008, 6, 760–769. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Critchley-Thorne, R.J.; Yan, N.; Nacu, S.; Weber, J.; Holmes, S.P.; Lee, P.P. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med. 2007, 4, e176. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Saito, R.; Sawada, Y.; Nakamura, M. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma. Int. J. Mol. Sci. 2021, 22, 1957. https://doi.org/10.3390/ijms22041957
Saito R, Sawada Y, Nakamura M. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma. International Journal of Molecular Sciences. 2021; 22(4):1957. https://doi.org/10.3390/ijms22041957
Chicago/Turabian StyleSaito, Ryuichi, Yu Sawada, and Motonobu Nakamura. 2021. "Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma" International Journal of Molecular Sciences 22, no. 4: 1957. https://doi.org/10.3390/ijms22041957